Trials / Completed
CompletedNCT05446233
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C] Antaitavir Hasophate in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of \[14C\] Antaitavir Hasophate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] Antaitavir Hasophate | 100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate |
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2023-01-02
- Completion
- 2023-01-02
- First posted
- 2022-07-06
- Last updated
- 2023-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05446233. Inclusion in this directory is not an endorsement.